Die Phase-3-Studie zu Simufilam, einem firmeneigenen kleinen Molekül von Cassava Sciences, auf das sowohl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback